Introduction
CagriSema is a breakthrough, once-weekly subcutaneous injection approved by the FDA in early 2026 for chronic weight management and Type 2 Diabetes. It is a fixed-dose combination of two powerful medications: Semaglutide (the active ingredient in Ozempic/Wegovy) and Cagrilintide (a long-acting amylin analogue). By targeting two different satiety pathways in the brain—the GLP-1 and the Amylin receptors—CagriSema produces more significant weight loss and blood sugar control than either medication used alone.
Usage and Indications
In the US, CagriSema is FDA-approved for:
- Chronic Weight Management: In adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition (e.g., hypertension, high cholesterol).
- Type 2 Diabetes Mellitus: To improve glycemic control in adults.
- It is highly sought after by patients who have reached a “weight-loss plateau” on single-agonist medications like Ozempic.
How to Take It (Dosage)
- Form: Subcutaneous injection in a pre-filled pen.
- Frequency: Once weekly, on the same day each week.
- Consistency: Can be taken at any time of day, with or without meals.
- Titration: Like other GLP-1s, patients start on a very low dose that is gradually increased every 4 weeks to minimize digestive side effects.
Side Effects
Because it combines two drugs, the side effects can be more pronounced initially:
- Very Common: Nausea, diarrhea, vomiting, and constipation.
- Common: Decreased appetite, headache, abdominal pain, and fatigue.
- Moderate: Heartburn (acid reflux) and injection site reactions.
- Serious (Rare): Pancreatitis, gallbladder disease, and potential kidney issues due to dehydration.
Precautions and Warnings
- Thyroid C-Cell Tumors: As with all GLP-1 medications, CagriSema has a boxed warning regarding the risk of thyroid tumors. It should not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC).
- Pancreatitis: Patients should stop use immediately if they experience severe, persistent abdominal pain.
- Hypoglycemia: While CagriSema itself doesn’t typically cause low blood sugar, the risk increases if used with insulin or sulfonylureas.
- Amylin-Specific Warning: Because amylin slows gastric emptying, the absorption of other oral medications might be delayed.
Interactions
- Oral Medications: Anything that requires rapid absorption (like antibiotics or pain relief) should be monitored, as CagriSema significantly slows digestion.
- Other GLP-1s: Do not combine CagriSema with Wegovy, Ozempic, or Mounjaro, as it already contains a GLP-1 component.
- Warfarin: US pharmacists recommend more frequent blood-clotting (INR) monitoring when starting this medication.
Storage
- Refrigeration: Store unused pens in the refrigerator (36°F to 46°F).
- Room Temperature: Once in use, the pen can typically be kept at room temperature for up to 30 days (check the 2026 label for exact specifics).
- Do Not Freeze: If the pen freezes, it must be discarded.
FAQ
- Is CagriSema better than Mounjaro? Clinical trials in 2026 suggest CagriSema may lead to even higher percentages of weight loss (up to 25% of body weight) compared to Zepbound/Mounjaro.
- Can I switch from Ozempic to CagriSema? Yes, many US doctors are switching patients to CagriSema if they have plateaued. A “washout period” is usually not required, but your starting dose will be adjusted.
- Does it cause more nausea? Because of the added Amylin component, some patients report slightly more nausea during the first two weeks compared to Ozempic.
- Will insurance cover CagriSema? As a new 2026 approval, it is being added to “Premium” formularies. US patients often require a “Prior Authorization” demonstrating that other medications were tried first.
- What is ‘Amylin’? It’s a hormone naturally co-secreted with insulin that makes you feel “full” and prevents blood sugar spikes after eating.
- Can I take it while pregnant? No. The FDA recommends discontinuing CagriSema at least 2 months before a planned pregnancy.
- Is there a pill version? As of April 2026, CagriSema is only available as a weekly injection.
- How fast will I see results? Most patients report a total loss of “food noise” within 24 hours of the first injection.
- What if I miss my dose? If it’s been 5 days or less, take it immediately. If more than 5 days have passed, skip that week and resume on your next scheduled day.
- Does it help with ‘Fatty Liver’? Early 2026 data shows CagriSema has promising results in reducing liver fat (MASH/MASLD).